37 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of POINT’s business.
Potential Conflicts of Interest. The POINT Board considered the potential conflict of interest created by the fact that POINT’s executive
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. These factors could
8-K
EX-99.1
ylhi4 93a7ckjhy8
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
vmfzti 6oixi
11 Jul 22
Prospectus supplement
4:32pm
POS AM
gdui1mk
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
6c2a7kanp0zft3ey3h
31 Mar 22
Prospectus supplement
11:42am
POS AM
u1pt 2bnm3
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
aidbkejq f59h
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.2
jjbiaus6urfq2
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.18
ifdl1fegkpn
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
i3nm4hl
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
f86 h15aih3cc0kig6
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.18
3muit7r7yh34g
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm